How to Get Lantus (Insulin Glargine) in Texas

What Exactly Is Lantus and Why Do Texas Patients Need It

Lantus is a long-acting basal insulin that provides 24-hour glucose coverage with a relatively flat pharmacokinetic profile and no pronounced peak. It is FDA-approved for adults and pediatric patients (age 6 and older) with type 1 diabetes and for adults with type 2 diabetes [1]. Texas has roughly 2.6 million adults living with diagnosed diabetes, according to the CDC's 2023 state-level estimates [2], making access to long-acting insulin a significant population-health concern across the state.

The active molecule, insulin glargine, is identical in branded Lantus and in FDA-approved biosimilars such as Basaglar and Rezvoglar. All three are dispensed at 100 units/mL (U-100); Toujeo (300 units/mL, also Sanofi) is a separate concentration requiring a distinct prescription. Choosing among them often comes down to insurance formulary placement and cost rather than clinical difference, because the FDA biosimilarity standard requires equivalent safety and efficacy [3].

The ORIGIN trial (N=12,537, median follow-up 6.2 years) demonstrated that insulin glargine did not increase major adverse cardiovascular events compared with standard care in people with dysglycemia, with a hazard ratio of 1.02 (95% CI 0.94 to 1.11, P<0.001 for non-inferiority) [4]. That finding gave clinicians greater confidence prescribing Lantus in high-cardiovascular-risk patients, a population that makes up a large share of Texas diabetes cases given the state's obesity prevalence.

Who Can Prescribe Lantus in Texas

Any licensed prescriber with DEA authority in Texas can write a Lantus prescription. That group includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Texas is a full-practice authority state for NPs under Senate Bill 406 (2023 legislative session), meaning NPs no longer require a collaborative practice agreement with a physician to prescribe controlled substances or other medications, including insulin [5].

PAs in Texas still require a supervising physician on file with the Texas Medical Board, but day-to-day prescribing of non-scheduled medications like insulin glargine does not require real-time physician co-signature. This matters for telehealth platforms, many of which staff NPs and PAs as primary prescribers.

For a first-time prescription, expect the provider to:

• Confirm a diagnosis of type 1 or type 2 diabetes using fasting glucose (≥126 mg/dL on two occasions) or HbA1c (≥6.5%), per American Diabetes Association 2024 Standards of Care [6].
• Review current medications to check for interactions with hypoglycemic agents.
• Establish a starting dose (typically 10 units at bedtime for type 2, or weight-based ~0.2 units/kg for type 1).
• Provide written injection training or refer the patient to a certified diabetes care and education specialist (CDCES).

How to Get Lantus Through Telehealth in Texas

Texas law explicitly permits telehealth prescribing for new and established patients following Senate Bill 1107 (89th Legislature, 2025), which extended and strengthened the telehealth framework first enacted during the COVID-19 public-health emergency [7]. A valid prescriber-patient relationship can be established via synchronous video, audio, or, for certain follow-up scenarios, asynchronous store-and-forward communication.

The practical steps are:

1. Book a visit with a Texas-licensed telehealth provider. Several platforms (including HealthRX) list Texas-licensed MDs, NPs, and PAs.
2. Complete intake forms covering your diabetes history, current HbA1c, and any prior insulin use.
3. Attend a video or phone visit, typically 15 to 30 minutes for a new patient.
4. Receive an electronic prescription sent directly to your preferred Texas pharmacy or a mail-order pharmacy licensed in Texas.
5. Pick up or receive delivery within 24 to 72 hours at most retail chains; 3 to 5 business days for mail order.

Labs are not always required for refills, but a new-start visit will almost always require a recent HbA1c (within 90 days) and a basic metabolic panel to assess renal function, because insulin dosing is adjusted when eGFR falls below 45 mL/min/1.73 m² [6].

The HealthRX clinical team uses a four-checkpoint decision framework for Lantus telehealth starts in Texas: (1) diagnosis confirmed by lab value, not symptom report alone; (2) HbA1c above 7.5% despite oral agents or dietary therapy; (3) renal function reviewed to rule out dose adjustment; (4) patient has or will receive a glucometer and training on hypoglycemia recognition before the first injection.

Which Texas Pharmacies Dispense Lantus

Lantus is available at virtually every major retail pharmacy chain operating in Texas, including CVS, Walgreens, H-E-B Pharmacy, Kroger Pharmacy, and Walmart Pharmacy. Walmart carries ReliOn brand insulin (regular and NPH, not glargine) over the counter at $25/vial, but Lantus and its biosimilars still require a prescription at Walmart.

503A Compounding Pharmacies. The Texas State Board of Pharmacy (TSBP) licenses 503A compounding pharmacies to prepare and dispense patient-specific compounds on a valid prescription. Insulin glargine may be compounded by 503A pharmacies in Texas when the FDA-approved product is unavailable or when a patient-specific formulation is medically necessary. TSBP rules require that 503A pharmacies operate under strict USP 797 sterile-compounding standards [8]. Compounded insulin is not bioequivalent-tested by the FDA, so clinical teams should document medical necessity carefully.

Mail-Order Options. Texas residents may use any mail-order pharmacy licensed in Texas, including Optum Rx, Express Scripts, CVS Caremark, and Amazon Pharmacy. Amazon Pharmacy ships Lantus 10-mL vials to most Texas ZIP codes within 2 to 5 business days with free Prime shipping. Express Scripts reports median delivery of 3.1 days to Texas addresses for temperature-sensitive biologics shipped in validated cold-chain packaging.

Insulin glargine must be stored at 36°F to 46°F (2°C to 8°C) before opening and may be kept at room temperature (below 86°F / 30°C) for up to 28 days after first use, per the Lantus prescribing information [1]. Texas summers routinely exceed 100°F, so mail-order cold-chain packaging and same-day refrigeration after delivery are genuinely important precautions.

Labs Required Before Starting Lantus in Texas

Most Texas prescribers and all telehealth platforms require a minimum lab panel before initiating insulin glargine. The ADA 2024 Standards of Care list HbA1c as the primary monitoring metric, with a target of <7.0% for most non-pregnant adults and <8.0% for patients with limited life expectancy or high hypoglycemia risk [6].

Commonly ordered labs for a new Lantus start:

• HbA1c. Confirms diagnosis and establishes baseline. A result of 6.5% or higher on two separate occasions meets the ADA diagnostic threshold [6].
• Fasting plasma glucose. Cross-checks HbA1c and guides initial dose selection.
• Comprehensive metabolic panel (CMP). Assesses hepatic function (insulin clearance) and renal function (eGFR for dose adjustment in CKD).
• C-peptide (optional). Helps distinguish type 1 from type 2 when clinical history is ambiguous; a fasting C-peptide <0.6 ng/mL suggests significant beta-cell loss [9].
• Thyroid-stimulating hormone (TSH). Thyroid dysfunction alters insulin sensitivity and is common in the type 1 population [10].

Quest Diagnostics and LabCorp both have extensive Texas draw-site networks. Several telehealth platforms send lab requisitions digitally, allowing patients to walk into a draw site without a paper order.

How Prior Authorization Works for Lantus in Texas

Prior authorization (PA) is required for Lantus by most Texas commercial insurers and by STAR+PLUS (Texas Medicaid managed care) for type 2 diabetes. The PA process typically requires:

• A confirmed diabetes diagnosis (ICD-10 code E11.x for type 2, E10.x for type 1).
• Documentation of HbA1c above the plan's threshold (commonly ≥7.5% or ≥8.0%).
• Evidence of a trial on at least one oral hypoglycemic agent (metformin first-line) for type 2 patients.
• For type 1, documentation is typically sufficient without an oral-agent trial requirement.

The American Diabetes Association's position statement on insulin access notes that PA delays have been associated with worse glycemic outcomes and increased hospitalizations for diabetic ketoacidosis [11]. Under Texas law, health plans must respond to standard PA requests within 3 business days and to urgent PA requests within 1 business day (Texas Insurance Code §843.348) [12].

If PA is denied, the prescriber can file an appeal. A peer-to-peer review request, filed by the prescribing physician or NP, is approved at a rate of approximately 60% to 70% in commercial plans based on published appeals data [13]. Telehealth platforms with in-house prior-authorization teams can handle this process on the patient's behalf.

Texas Medicaid Coverage for Lantus

Texas Medicaid (STAR, STAR+PLUS, CHIP) covers Lantus for type 1 diabetes without a quantity limit. For type 2 diabetes, Lantus is not on the Texas Medicaid preferred drug list (PDL) as of the current 2025 PDL update [14]. Patients with type 2 diabetes who are enrolled in Texas Medicaid are directed to biosimilar insulin glargine products (Basaglar) or NPH insulin before Lantus will be authorized.

Managed care organizations within Texas Medicaid (e.g., UnitedHealthcare Community Plan, Molina Healthcare of Texas, Community Health Choice) have individual formularies that may differ from the state PDL. Patients should call the member services number on their insurance card and ask specifically whether insulin glargine 100 units/mL is covered under their plan and what tier it is placed on.

Cost and Patient Assistance Programs for Lantus in Texas

Lantus without insurance costs approximately $270 to $320 per 10-mL vial at Texas retail pharmacies as of mid-2025. Several programs reduce this substantially:

Sanofi Insulins Valyou Savings Program. Sanofi offers Lantus at $99 per 1 to 3 vials per month for uninsured or underinsured patients. Income verification is not required. Eligible patients pay $99 regardless of vial count within the monthly limit [15].

GoodRx and similar discount cards. GoodRx prices for Lantus 10 mL at Texas pharmacies range from $88 to $145 per vial depending on the pharmacy and the patient's ZIP code, based on publicly available GoodRx data.

Sanofi Patient Assistance Program (PAP). Patients with income at or below 400% of the federal poverty level who lack adequate insurance may receive Lantus at no cost through the Sanofi PAP. Applications are available through Sanofi's patient support line (1-888-847-4877) or through NeedyMeds.org.

Mark Cuban's Cost Plus Drugs. As of 2025, insulin glargine biosimilars are available through Cost Plus Drugs at cost-plus-15%, which in practice prices a vial of Basaglar (insulin glargine) below $50 for patients paying cash.

The Inflation Reduction Act of 2022 capped out-of-pocket insulin costs at $35 per month for Medicare Part D beneficiaries effective January 1, 2023. Texas Medicare patients on Part D should not pay more than $35 per month for any covered insulin product [16].

Transferring an Existing Lantus Prescription to Texas

Patients relocating to Texas from another state can transfer a Lantus prescription to a Texas pharmacy under federal and state rules. Because insulin glargine is not a controlled substance (Schedule II through V), there is no federal barrier to interstate prescription transfer. Texas Pharmacy Rule §291.34 permits a pharmacy to accept a transferred prescription from another state as long as the original prescription is valid and has refills remaining [17].

Practically, the receiving Texas pharmacy will call or fax the out-of-state pharmacy, confirm the prescription details, and transfer the remaining refills. The entire process typically takes under one hour for retail chains with inter-state reciprocity agreements (CVS, Walgreens, Walmart).

For telehealth patients whose prescriptions were written by an out-of-state provider who is not licensed in Texas, a new prescription from a Texas-licensed provider is required. This is a brief process, often completed in a single telehealth visit with an existing lab panel.

Dosing and Injection Basics for New Lantus Users in Texas

Insulin glargine is injected subcutaneously, not intravenously. Injection sites include the abdomen (preferred for fastest absorption), the outer thigh, or the upper arm. The FDA-approved prescribing information recommends rotating sites within the same region to prevent lipohypertrophy [1].

Starting doses:

• Type 2 diabetes, insulin-naive: 10 units once daily at the same time each day, titrated upward by 2 units every 3 days until fasting glucose is 80 to 130 mg/dL.
• Type 1 diabetes: 0.2 units/kg once daily as the basal component, with a separate rapid-acting insulin for meals.
• Patients switching from NPH or other basal insulins: Unit-for-unit conversion is generally safe, though some patients require a 20% dose reduction when switching from twice-daily NPH to once-daily glargine to avoid nocturnal hypoglycemia [6].

Hypoglycemia is the most common adverse effect. Symptoms include sweating, tremor, confusion, and palpitations. Texas patients should keep fast-acting glucose (glucose tablets, 4 oz juice) within reach, particularly during the first 2 weeks of dose titration. The ADA recommends treating hypoglycemia (blood glucose <70 mg/dL) with 15 grams of fast-acting carbohydrate, then rechecking in 15 minutes [6].

Monitoring After Starting Lantus in Texas

After initiating insulin glargine, the ADA recommends repeating HbA1c every 3 months until targets are stable, then every 6 months [6]. Continuous glucose monitors (CGMs) such as the Dexterity G7 or Libre 3 are now covered by Texas Medicaid for type 1 patients and by most commercial plans for both type 1 and type 2. CGM data provides a time-in-range metric (target: more than 70% of readings between 70 and 180 mg/dL) that complements HbA1c.

Annual labs for ongoing Lantus users should include a urine albumin-to-creatinine ratio (ACR) to screen for diabetic nephropathy, a lipid panel, and a CMP. The National Kidney Foundation links persistent HbA1c above 8.0% with a 2.3-fold increased risk of nephropathy progression, underscoring the value of consistent basal insulin therapy when oral agents alone are insufficient [18].